NeoTX Therapeutics, Ltd. (NeoTX), a clinical-stage immuno-oncology company, today announced a presentation on the company’s lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C.
REHOVOT, Israel, Nov. 9, 2021 /PRNewswire/ -- NeoTX Therapeutics, Ltd. (NeoTX), a clinical-stage immuno-oncology company, today announced a presentation on the company’s lead program, naptumomab estafenatox (NAP), at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting being held November 10-14, 2021 at the Walter E. Washington convention Center, Washington D.C. The poster presentation will highlight preclinical data demonstrating that NAP enhances CAR-T cells potency and can boost CAR-T efficacy against solid tumors. Details on the poster presentation are as follows:
About NeoTX NeoTX is a clinical-stage immuno-oncology company which is developing targeted anticancer immunotherapies utilizing its proprietary Tumor Targeted Superantigen (TTS) platform. TTS binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells that are then redirected from the periphery to the tumor to mount an immune response. The company’s lead TTS molecule, naptumomab estafenatox (NAP) is currently in clinical development for advanced solid tumors. For more information, please visit www.neotx.com Media Contact: Investor Contact:
View original content:https://www.prnewswire.com/news-releases/neotx-therapeutics-to-present-at-the-society-for-immunotherapy-of-cancers-36th-annual-meeting-301419547.html SOURCE NeoTX |